● GlobeNewsWireNov 6, 2026 · 16:01 ETCOMPANY'S OWN WORDS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, …
● GlobeNewsWireNov 4, 2026 · 07:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 23
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
– Received European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination), marking the first regulatory approval of obicetrapib worldwide –…
● GlobeNewsWireNov 3, 2026 · 08:00 ETCOMPANY'S OWN WORDS
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
NAARDEN, The Netherlands and MIAMI, Nov. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, …
NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 1-Year Low – Should You Sell?
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Wednesday. The company traded as low as $20.04 and last traded at $20.19, with a volume …
● GlobeNewsWireOct 2, 2026 · 16:01 ETCOMPANY'S OWN WORDS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, …
● GlobeNewsWireSep 29, 2026 · 08:00 ETCOMPANY'S OWN WORDS
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease
- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer's disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based…
Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco®
Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo (obicetrapib en monoterapia) y Evlarco (combinación a dosis…
● GlobeNewsWireSep 21, 2026 · 09:00 ETCOMPANY'S OWN WORDS
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile-…
● Defense WorldSep 11, 2026 · 03:45 ETEARNINGS EXPECTED BY FEB 23
Biogen (NASDAQ:BIIB) versus NewAmsterdam Pharma (NASDAQ:NAMS) Financial Analysis
NewAmsterdam Pharma (NASDAQ: NAMS - Get Free Report) and Biogen (NASDAQ: BIIB - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of th…
● GlobeNewsWireSep 3, 2026 · 16:01 ETCOMPANY'S OWN WORDS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral,…
● GlobeNewsWireAug 26, 2026 · 08:00 ETCOMPANY'S OWN WORDS
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, …
● Defense WorldAug 16, 2026 · 03:53 ETEARNINGS EXPECTED BY FEB 23
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Handelsbanken Fonder AB
Handelsbanken Fonder AB lessened its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) by 70.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The in…
Article counts from the last market-wide feed page, across every symbol we track and not just NAMS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.